Naris Nilubol, M.D., F.A.C.S.

Assistant Clinical Investigator

Surgical Oncology Program


Building 10 - Room 45952
Bethesda, MD 20892


Research Topics

Dr. Nilubol is the Principle Investigator of the protocol that comprehensively analyzes molecular alterations in endocrine cancers that lead to tumor progression and metastasis. He is the Principle Investigator who aims to risk-stratify patients with von Hippel-Lindau disease (VHL)-associated pancreatic neuroendocrine tumors by combining the advanced imaging modalities, genetic information, and the molecular mechanisms involved in early metastasis identified by mRNA profiling, metabolomics, and exosomes.

Dr. Nilubol’s research program focuses on the identification of novel targeted therapeutics in endocrine cancers such as adrenocortical cancer and aggressive variants of thyroid cancers. Patients with these rare and aggressive cancers do not have treatment options with a durable response. Dr. Nilubol collaborates with a number of NIH intramural investigators and uses the quantitative high-throughput drug screening method to identify candidate compounds from several pharmaceutical libraries containing approved drugs and natural compounds. Candidate compounds are being investigated in preclinical studies with the goal to translate the effective combinations of drugs to clinical trials in patients with advanced endocrine cancers. However, most newly-discovered drugs do not show anti-tumor efficacy because many characteristics of solid cancers prohibit effective drug delivery. Thus, Dr. Nilubol’s research focuses on targeting the tumor microenvironment to reduce interstitial fluid pressure and increase drug delivery. To accomplish this goal, he utilizes gold nanomedicine carrying vascular disrupting agent (tumor necrosis factor-alpha) specifically targeting tumor cells and their blood supply in collaborating with extramural investigators. The current research aim is to understand how TNF-α works in the tumor microenvironment and how to induce the response downstream to TNF-α in tumors refractory to TNF-α.


Dr. Nilubol graduated from Chulalongkorn University Medical Center, Bangkok, Thailand with honors. He completed a surgical research fellowship followed by general surgery training in 2005 at The Mount Sinai Hospital, New York, NY. Following surgery residency, Dr. Nilubol completed the Endocrine Oncology Surgery fellowship at Rush University Medical Center, Chicago, IL. Dr. Nilubol was on faculty at Mount Sinai Hospital, NY, before being recruited to NCI. There are over 140 peer-reviewed publications and several book chapters that Dr. Nilubol has authored.

Selected Publications

  1. El Lakis M, Nockel P, Gaitanidis A, Guan B, Agarwal S, Welch J, Simonds WF, Weinstein L, Marx S, Nilubol N, Patel D, Merkel R, Tirosh A, Kebebew E. Probability of Positive Genetic Testing Results in Patients with Family History of Primary Hyperparathyroidism. J Am Coll Surg. 2018;226(5):933-938.
  2. El Lakis M, Nockel P, Guan B, Agarwal S, Welch J, Simonds WF, Marx S, Li Y, Nilubol N, Patel D, Yang L, Merkel R, Kebebew E. Familial isolated primary hyperparathyroidism associated with germline GCM2 mutations is more aggressive and has a lesser rate of biochemical cure. Surgery. 2018;163(1):31-34.

Related Scientific Focus Areas

This page was last updated on Friday, February 9, 2024